Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
131.2 ^USD	+0.37%		+4.31%	+20.34%

Apr. 26	Wolfe Research Adjusts Price Target on Merck & Company to $151 From $141	MT
Apr. 26	Morgan Stanley Adjusts Merck & Co.'s Price Target to $132 From $128	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Merck: Q1 Earnings Snapshot	Apr. 25	AQ
Merck Announces First-Quarter 2024 Financial Results	Apr. 25	BU
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy	Apr. 19	AQ
Merck Manuals Celebrates Its 125th Year	Apr. 17	AQ
Moderna cancer vaccine shows promise in initial tests; share skyrockets	Apr. 12	AQ
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer	Apr. 05	AQ
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer	Apr. 04	BU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	Apr. 03	AQ
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	BU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	Apr. 02	AQ
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25	Apr. 01	BU
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults	Mar. 28	BU
Elekta partners with MSD to enhance kidney cancer care using digital solutions	Mar. 28	AQ
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024	Mar. 27	AQ
Thinking about buying stock in Diamondback Energy, Merck, High Tide, Rumble, or SNDL?	Mar. 27	PR
FDA Approves Merck's WINREVAIR, a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension	Mar. 27	AQ
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)	Mar. 26	BU
Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region	Mar. 26	AQ
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA plus Maintenance LYNPARZA for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer	Mar. 22	AQ
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer	Mar. 21	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Press Releases

Filters